Yahoo Canada Web Search

Search results

1. www.fiercepharma.com › pharma › sarepta-duchenneFDA broadens label for Sarepta's Duchenne gene therapy Elevidys

   www.fiercepharma.com › pharma › sarepta-duchenne

   • Cached

   Jun 21, 2024 · On Thursday, the FDA expanded the label for Elevidys (delandistrogene moxeparvovec-rokl) to all DMD patients ages 4 and older. It’s a major boost for the first gene therapy to treat the ...

   • Author: Kevin Dunleavy

2. pharmaphorum.com › news › roche-starts-new-four-yearRoche starts new four-year trial of Alzheimer's drug ...

   pharmaphorum.com › news › roche-starts-new-four-year

   • Cached

   1 day ago · With prospects of an early, accelerated approval for Roche's Alzheimer's disease candidate gantenerumab looking diminished, the drugmaker has launched a new four-year trial in the hope of...

3. www.fiercebiotech.com › medtech › roche-levels-tradeRoche levels trade secrets lawsuit against Stanford and its ...

   www.fiercebiotech.com › medtech › roche-levels-trade

   • Cached

   3 days ago · Roche has filed a lawsuit against Stanford University and its spinout Foresight Diagnostics, saying the young cancer test developer was built upon trade secrets it acquired for detecting tumor...

4. pharmaphorum.com › news › roche-builds-gene-therapyRoche builds gene therapy portfolio with SpliceBio deal

   pharmaphorum.com › news › roche-builds-gene-therapy

   • Cached

   3 days ago · Roche’s gene therapy unit Spark has added to its pipeline in inherited retinal diseases (IRDs) with a $216 million alliance with Spanish biotech SpliceBio.

5. www.roche.com › media › releasesRoche - Doing now what patients need next

   www.roche.com › media › releases

   Jun 25, 2024 · Roche is dedicated to advancing patient care by pioneering innovative healthcare solutions across pharmaceuticals and diagnostics.

6. www.sarepta.comSarepta Therapeutics | Biopharmaceutical Company for Rare ...

   www.sarepta.com

   • Cached

   1 day ago · Sarepta's gene therapy engine at work in LGMD2E research. Sarepta’s gene therapy engine provides a framework for creating a steady stream of new therapies for devastating diseases, such as limb-girdle muscular dystrophies. Learn more about our LGMD research.

7. People also ask

   Why is Roche pursuing a new therapeutic field?

   • WHY IT'S IMPORTANT Roche is pursuing several therapeutic fields to offset falling oncology sales, setting a high deal pace to restore its development pipeline that was hit by major trial setbacks in Alzheimer's and cancer immunotherapy in 2022.

   Roche partners with Ascidian Therapeutics to develop gene therapies

   health.economictimes.indiatimes.com/news/pharma/mergers-acquisitions/roche-partners-with-ascidian-therapeutics-to-develop-gene-therapies/111088577

   See all results for this question

   Does Sarepta have a partnership with Roche?

   • As for Sarepta's $1 billion-plus partnership with Roche, which was established in 2019, the Massachusetts-based company is responsible for regulatory approval and commercialization of Elevidys in the U.S., as well as manufacturing, while Roche is responsible for regulatory approval and commercialization of Elevidys in the rest of the world.

   FDA broadens label for Sarepta's Duchenne gene therapy Elevidys

   www.fiercepharma.com/pharma/sarepta-duchenne-elevidys-label-expansion-fda-decision

   See all results for this question

   Will Roche move ahead with Gantenerumab?

   • There had been speculation last year that Roche would move ahead with a quick filing for gantenerumab after Biogen got a controversial accelerated approval for Aduhelm (aducanumab) using amyloid clearance as a surrogate endpoint, although that was downplayed by the company.

   Roche starts new four-year trial of Alzheimer's drug gantenerumab

   pharmaphorum.com/news/roche-starts-new-four-year-trial-of-alzheimers-drug-gantenerumab

   See all results for this question

8. health.economictimes.indiatimes.com › news › pharmaRoche partners with Ascidian Therapeutics to develop gene ...

   health.economictimes.indiatimes.com › news › pharma

   • Cached

   Jun 18, 2024 · London: Swiss drugmaker Roche will team up with privately held biotech Ascidian Therapeutics to develop gene therapies targeting difficult to treat neurological diseases, the Boston-based startup said on Tuesday. WHY IT'S IMPORTANT.